Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-DOTATOC
- Development stage
- Unknown
- Lead developer
- Evergreen Theragnostics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
68Ga-DOTATOC is a radiopharmaceutical imaging agent consisting of the positron-emitting radioisotope gallium-68 (68Ga) complexed with the somatostatin analog DOTATOC (DOTA-0-Phe1-Tyr3-octreotide). It functions as a diagnostic PET tracer by binding with high affinity to somatostatin receptors, specifically subtype 2 (SSTR2), which are often overexpressed in various malignancies. While primarily approved for imaging neuroendocrine tumors, it is being investigated by the University Hospital, Grenoble (CHU Grenoble Alpes) in the DOTABREAST Phase 3 clinical trial. This study evaluates the agent's ability to detect SSTR2 expression in patients with metastatic breast cancer, potentially offering a more specific imaging modality compared to conventional 18F-FDG PET for characterizing metastatic lesions across different breast cancer subtypes.
- Other names
- Gallium-68 DOTATOCGallium68 DOTATOCGallium 68 DOTATOC68Ga-DOTA-Tyr3-octreotideDOTABREAST68Ga-DOTA-TOC
02
Targets
SSTR3 (Somatostatin receptor 3)SSTR1 (Somatostatin Receptor Type 1)SSTR5 (Somatostatin receptor 5)SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on 68Ga-DOTATOC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-DOTATOC.